Tonix Pharmaceuticals Holding Corp (LTS:0A4T)
$ 134.6 0 (0%) Market Cap: 17.80 Mil Enterprise Value: 12.04 Mil PE Ratio: 0 PB Ratio: 0.39 GF Score: 31/100

Tonix Pharmaceuticals Holding Corp at ThinkEquity Conference Transcript

Oct 19, 2023 / 12:00PM GMT
Release Date Price: $134.6
Jessica Morris
Tonix Pharmaceuticals Holding Corp. - COO

It's great to be here today presenting at the ThinkEquity Conference on behalf of Tonix Pharmaceutics. I am Jessica Morris, Chief Operating Officer. We are a publicly traded company on Nasdaq, so this is our standard safe harbor statement. I will be making forward-looking statements, so I refer you to our SEC filings for complete information.

So who is Tonix Pharmaceuticals? We are a biopharmaceutical company committed to developing as well as marketing therapeutics to treat pain, neurologic, psychiatric, addiction conditions, which all fall under our CNS or Central Nervous System portfolio. But we also focus on other areas of high unmet need, we believe these areas are within immunology, infectious disease, and rare disease. But today, I'm going to mostly focus on our CNS portfolio, this has our latest-stage asset, as well as the assets with the nearest term milestones.

So again, we are a biopharmaceutical company, but we have evolved a lot over the last decade since we've been publicly traded, from a company with just a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot